financetom
Business
financetom
/
Business
/
Embecta's Fiscal Q4 Adjusted Earnings Rise, Revenue Falls; Issues Fiscal 2026 Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Embecta's Fiscal Q4 Adjusted Earnings Rise, Revenue Falls; Issues Fiscal 2026 Guidance
Nov 25, 2025 4:08 AM

06:52 AM EST, 11/25/2025 (MT Newswires) -- Embecta ( EMBC ) reported fiscal Q4 adjusted earnings Tuesday of $0.50 per diluted share, up from $0.45 a year earlier.

Four analysts polled by FactSet expected $0.46.

Revenue for the quarter ended Sept. 30 was $264 million, compared with $286.1 million a year earlier.

Analysts surveyed by FactSet expected $265.7 million.

For fiscal 2026, the company said it expects adjusted EPS of $2.80 to $3 per diluted share. Four analysts polled by FactSet expect $2.95.

Revenue for the fiscal year is expected in the range of $1.07 billion to $1.09 billion. Analysts surveyed by FactSet expect $1.08 billion.

Shares of the company were up 1.1% in recent Tuesday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US FCC opens formal inquiry into use of data caps by telecom firms
US FCC opens formal inquiry into use of data caps by telecom firms
Oct 15, 2024
WASHINGTON (Reuters) - The Federal Communications Commission said Tuesday it is opening a formal inquiry into the use of data caps by telecom firms and how they impact consumers and competition. For most people in the United States, rationing their internet usage would be unthinkable and impractical. But, for millions, limitations on how much data they can use online is...
GlaxoSmithKline sues Moderna for US patent infringement over COVID vaccines
GlaxoSmithKline sues Moderna for US patent infringement over COVID vaccines
Oct 15, 2024
Oct 15 (Reuters) - GlaxoSmithKline sued Moderna ( MRNA ) in Delaware federal court on Tuesday for allegedly violating GSK's patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax. The lawsuit said Moderna's ( MRNA ) lipid nanoparticles for transporting mRNA into the human body infringe several GSK patents covering similar innovations. GSK filed a related...
Resmed Insider Sold Shares Worth $1,015,925, According to a Recent SEC Filing
Resmed Insider Sold Shares Worth $1,015,925, According to a Recent SEC Filing
Oct 15, 2024
10:12 AM EDT, 10/15/2024 (MT Newswires) -- Kaushik Ghoshal, Chief Commercial Officer, SaaS, on October 11, 2024, sold 4,260 shares in Resmed ( RMD ) for $1,015,925. Following the Form 4 filing with the SEC, Ghoshal has control over a total of 21,788 shares of the company, with 21,788 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/943819/000112760224025433/xslF345X05/form4.xml Price: 242.66, Change: +1.94, Percent...
Update: Market Chatter: Shell Urged to Pay Over $1 Billion in Damages by Russian Government
Update: Market Chatter: Shell Urged to Pay Over $1 Billion in Damages by Russian Government
Oct 15, 2024
10:12 AM EDT, 10/15/2024 (MT Newswires) -- (Updates with Shell's reply in the third paragraph and recent stock move in the last paragraph.) Shell (SHEL) is being asked to pay at least 1 billion euros ($1.09 billion) in damages by the Russian General Prosecutor's office, the RIA news agency reported Tuesday, citing the Moscow Arbitration court. Details of the general...
Copyright 2023-2026 - www.financetom.com All Rights Reserved